Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase

10.12.2022 - Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data from the Company’s ongoing Phase 1 study of ...

Related Keywords

Texas , United States , American , Francesco Galimi , Adicet Bio , Chen Schor , Adicet Bio Inc , Division Of Cancer Medicine , International Prognostic Index , University Of Texas Md Anderson Cancer Center , Drug Administration , Company Twitter , American Society For Transplantation , Nasdaq , Exchange Commission , Department Of Lymphoma Myeloma , European Medicines Agency , Department Of Lymphoma , Preliminary Efficacy Data , Senior Vice President , Chief Medical Officer , Chief Executive Officer , Sattva Neelapu , Cytokine Release Syndrome , Safety Data , Efficacy Evaluable Patients , Common Terminology Criteria , Adverse Events , American Society , Cellular Therapy , Biologics License Application , Marketing Authorization Application , Conference Call , Cancer Medicine , Cancer Center , Fast Track Designation , Private Securities Litigation Reform Act , Annual Report , Adicet Bio Stock ,